<DOC>
	<DOCNO>NCT02036359</DOCNO>
	<brief_summary>To compare clinical response ( complete response partial response ) RECIST ) rate RECIST erlotinib monotherapy docetaxel plus cisplatin chemotherapy</brief_summary>
	<brief_title>Erlotinib Monotherapy Versus Docetaxel Cisplatin Neoadjuvant Therapy Patients stageIIIA Lung ca</brief_title>
	<detailed_description>open-label , multi-centre , randomize , phase II study evaluate efficacy erlotinib monotherapy vs. docetaxel plus cisplatin chemotherapy . Patients histological documented stage IIIA lung adenocarcinoma . The tumor specimen examine EGFR gene mutation ( Exon 18-21 ) . Those exon 19 deletion L858R , G719X , L861Q mutation randomize erlotinib monotherapy docetaxel plus cisplatin chemotherapy . The randomization stratify center Study treatment Patients receive treatment 9 week unless disease progression , unacceptable toxicity death . Erlotinib arm : Patients erlotinib arm take erlotinib 150mg/day 9 week unless disease progression , unacceptable toxicity death . Chemotherapy arm : Patients chemotherapy arm receive 3 cycle ( 9 week ) chemotherapy docetaxel 35mg/m2 IV day 1 day 8 , cisplatin 75mg/m2 day 8 . Treatment failure include patient fail complete 3 cycle ( 9 week ) study treatment due disease progression unacceptable toxicity . Patients disease progression terminate study treatment undergo surgical resection follow disease progression note , study end . Survival record analyze . If progressive disease unacceptable toxicity occur study treatment , patient treat discretion investigator accord local protocol . Please note : • If judge investigator best interest patient , patient discontinue study treatment may receive second-line treatment .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>• Age ≥ 18 year , male female Able comply protocol Histologically document stage IIIA lung adenocarcinoma ECOG performance status 02 If patient use coumarin ( coumarin ) ( also call coumadin warfarin ) , patient applies drug previous 7 day experiment stop medicine , change use medicine . Life expectancy &gt; 12 week Tumor specimen EGFR gene mutation exon 19 deletion L858R , G719X , L861Q mutation Adequate hematological function : ANC ≥ 1.5 x 109/L ; platelet ≥ 100 x 109/L , Hb ≥ 9 g/dL Data INR PTT available patient take anticoagulant concomitantly , INR ≤ 1.5 PTT ≤ 1.5 time upper limit normal ( x ULN ) within 7 day prior start study treatment Adequate liver function : serum bilirubin ≤ 1.5 x ULN ; transaminases ≤ 2.5 x ULN Adequate renal function : 24hour urine creatinine clearance creatinine clearance measure calculated accord formula Cockroft Gault ≥ 60ml/min Negative serum pregnancy test within 7 day start study treatment premenopausal woman Written inform consent . Patients willing complete FACTL , ED5Q , pharmacoeconomic questionnaire • Prior chemotherapy treatment another systemic anticancer agent ( example monoclonal antibody , tyrosine kinase inhibitor ) Mixed adenocarcinoma histological type lung cancer Unable take oral medicine Pregnant lactate woman Fertile men woman childbearing potential use adequate contraception ( oral contraceptive , intrauterine device barrier method contraception conjunction spermicidal jelly surgically sterile ) Malignancies NSCLC within 5 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , DCIS treat surgically curative intent Treatment investigational agent , participation another clinical trial within 30 day prior start study treatment Known hypersensitivity study drug Concurrent cancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Non-small Cell Lung Cancer ( NSCLC )</keyword>
</DOC>